Timolol
- Generic Name
- Timolol
- Brand Names
- Azarga, Betimol, Combigan, Cosopt, Duotrav, Istalol, Timoptic, Xalacom
- Drug Type
- Small Molecule
- Chemical Formula
- C13H24N4O3S
- CAS Number
- 26839-75-8
- Unique Ingredient Identifier
- 5JKY92S7BR
- Background
Timolol is a nonselective beta-adrenergic antagonist given in an eye drop solution to reduce intraocular pressure, or pressure in the eyes. It is also used in tablet form as a drug to treat hypertension. Timolol was first approved by the FDA in 1978. This drug is marketed by several manufacturers and is an effective agent for the management of conditions such as open-angle glaucoma and hypertension.
- Indication
Ophthalmic timolol is indicated for the treatment of increased intraocular pressure in patients with ocular hypertension or open-angle glaucoma. The oral form of this drug is used to treat high blood pressure. In certain cases, timolol is used in the prevention of migraine headaches.
- Associated Conditions
- Increased Intra Ocular Pressure (IOP), Migraine, Ocular Hypertension, Open Angle Glaucoma (OAG)
Bimatoprost Ocular Insert Compared to Topical Timolol Solution in Patients With Glaucoma or Ocular Hypertension
- Conditions
- Ocular HypertensionPrimary Open-Angle Glaucoma
- Interventions
- First Posted Date
- 2013-08-05
- Last Posted Date
- 2018-04-20
- Lead Sponsor
- ForSight Vision5, Inc.
- Target Recruit Count
- 169
- Registration Number
- NCT01915940
- Locations
- 🇺🇸
Ophthalmology Associates PC, Fort Worth, Texas, United States
🇺🇸UNC Kittner Eye Center, Chapel Hill, North Carolina, United States
🇺🇸Scripps Clinic Torrey Pines, La Jolla, California, United States
An Efficacy and Safety Study of Bimatoprost 0.01% Alone Compared With Travoprost 0.004% and Timolol 0.5% in Subjects With Glaucoma or Ocular Hypertension
- Conditions
- GlaucomaOcular Hypertension
- Interventions
- First Posted Date
- 2013-06-19
- Last Posted Date
- 2015-11-30
- Lead Sponsor
- Allergan
- Target Recruit Count
- 93
- Registration Number
- NCT01881126
A Clinical Trial of Pulsed-dye Laser Versus Timolol Topical Solution Versus Observation on the Growth of Hemangioma in Newborn
- Conditions
- Hemangioma
- Interventions
- Device: Pulsed dye laser
- First Posted Date
- 2013-06-07
- Last Posted Date
- 2023-11-02
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 126
- Registration Number
- NCT01873131
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
Multi-Arm Feasibility Study Evaluating OTX-TP Compared to Timolol in Treatment of Subjects With Open Angle Glaucoma
- Conditions
- Glaucoma
- Interventions
- Drug: OTX-TPb ~3µg/day over 3 months with natural tears dropsDrug: OTX-TPa ~4µg/day over 2 mos. with natural tears drops
- First Posted Date
- 2013-05-03
- Last Posted Date
- 2016-12-12
- Lead Sponsor
- Ocular Therapeutix, Inc.
- Target Recruit Count
- 41
- Registration Number
- NCT01845038
- Locations
- 🇿🇦
Umhlanga Hospital Medical Centre, Durban, South Africa
Topical Anti-angiogenic Therapy for Telangiectasia in HHT: Proof of Concept
- Conditions
- Hereditary Hemorrhagic Telangiectasia
- Interventions
- Drug: placebo saline drops
- First Posted Date
- 2012-12-18
- Last Posted Date
- 2023-09-21
- Lead Sponsor
- Unity Health Toronto
- Target Recruit Count
- 5
- Registration Number
- NCT01752049
- Locations
- 🇨🇦
St. Michael's Hospital, Toronto, Ontario, Canada
Comparing Safety and Efficacy of BOL-303259-X With Timolol Maleate in Subjects With Open-Angle Glaucoma or Ocular Hypertension
- Conditions
- Open-Angle GlaucomaOcular Hypertension
- Interventions
- First Posted Date
- 2012-12-17
- Last Posted Date
- 2018-11-07
- Lead Sponsor
- Bausch & Lomb Incorporated
- Target Recruit Count
- 420
- Registration Number
- NCT01749904
- Locations
- 🇺🇸
Bausch & Lomb Inc., Rochester, New York, United States
Comparing the Safety and Efficacy of BOL-303259-X Ophthalmic Solution With Timolol Maleate Ophthalmic Solution in Subjects With Open-Angle Glaucoma or Ocular Hypertension
- Conditions
- Open-Angle GlaucomaOcular Hypertension
- Interventions
- First Posted Date
- 2012-12-17
- Last Posted Date
- 2018-11-21
- Lead Sponsor
- Bausch & Lomb Incorporated
- Target Recruit Count
- 420
- Registration Number
- NCT01749930
- Locations
- 🇺🇸
Bausch & Lomb Inc., Rochester, New York, United States
Effect of Topical Glaucoma Therapy on Tear Film Stability in Healthy Subjects
- Conditions
- Healthy
- Interventions
- Device: Hylo-Comod®Device: Genteal HA®Drug: Timophtal sine® 0.5%Device: Thealoz®
- First Posted Date
- 2012-12-11
- Last Posted Date
- 2016-12-02
- Lead Sponsor
- Medical University of Vienna
- Target Recruit Count
- 38
- Registration Number
- NCT01746602
- Locations
- 🇦🇹
Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria
BOL-303259-X With Timolol 0.5% in Subjects With Open-Angle Glaucoma or Ocular Hypertension
- Conditions
- Ocular HypertensionOpen Angle Glaucoma
- Interventions
- First Posted Date
- 2012-10-16
- Last Posted Date
- 2018-09-04
- Lead Sponsor
- Bausch & Lomb Incorporated
- Target Recruit Count
- 25
- Registration Number
- NCT01707381
- Locations
- 🇺🇸
University of California San Diego, La Jolla, California, United States
A Study Assessing the Safety and Ocular Hypotensive Efficacy of AR-12286 in Patients With Elevated Intraocular Pressure for 3 Months
- Conditions
- Open-angle GlaucomaOcular Hypertension
- Interventions
- Drug: AR-12286 Ophthalmic Solution 0.7%Drug: AR-12286 Ophthalmic Solution 0.5%
- First Posted Date
- 2012-10-03
- Last Posted Date
- 2023-08-22
- Lead Sponsor
- Aerie Pharmaceuticals
- Target Recruit Count
- 211
- Registration Number
- NCT01699464
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.